Recent articles
Here's Why Akorn Stock Rose as Much as 14.4% Today
The embattled generic-pharmaceutical manufacturer earned two new product approvals.
Better Buy: Albemarle vs. Sociedad Quimica y Minera
They're two of the world's largest lithium producers, but one is better positioned for the future.
2 Stocks You Can Buy and Hold Forever
These businesses have formidable advantages in future-proofed industries.
2 Top Stocks You Can Buy on Sale
The S&P 500 has rarely been more expensive than it is today. That doesn't mean bargain-hunting investors are out of luck.
Pump the Brakes on the Illumina and Pacific Biosciences Deal
The United Kingdom's Competition and Markets Authority has opened an investigation into the acquisition. What happens now?
Will a Slowing Economy Derail This Fast-Growing Infrastructure Stock?
U.S. Concrete says the construction cycle hasn't reached its peak. Do economic forecasts suggest otherwise?
Here's Why Amyris Is Soaring Today
Another day, another transaction. Is the synthetic biology pioneer better positioned to execute now?
Here's Why Marker Therapeutics Fell as Much as 11.5% Today
An abstract detailing one of the company's clinical programs was rejected from an important industry meeting.
1 Under-the-Radar Healthcare Stock Wall Street Is Overlooking
This Israeli-based pharma company is poised to receive regulatory approval for its first product in the second half of 2019.
Here's Why Clovis Oncology Stock Dropped as Much as 13% Today
The company decided to discontinue an important clinical trial.
Here's Why Amyris Jumped as Much as 28.9% Today
The business received a small lifeline from one of its largest shareholders.
Nutrien Is Quietly Positioning Itself for the Future of Agriculture
Fertilizer companies have largely ignored an approaching wave of digital and biotech competition. Nutrien is taking the risks -- and opportunities -- seriously.
Why Amyris Stock Fell 30.9% Today
Shares of the synthetic biology pioneer have risen and fallen by double digits many days in recent weeks.
These 2 Stocks Survived the Trade War, but Wall Street Hasn't Noticed
International Paper and WestRock have been humming along, but shares of America's pulp and paper giants are down significantly since the start of 2018.
2 Top Stocks to Buy in April
Many companies will report quarterly earnings later this month and in early May, which makes it a good time for opportunistic investors to be on high alert.
Here's Why Rigel Pharmaceuticals Gained 17.3% in March
The pharma company announced full-year 2018 operating results.
Here's Why Puma Biotechnology Rose 39.5% in March
The pharma company announced full-year 2018 operating results and multiple business updates.
Here's Why Jounce Therapeutics Rose 39.3% in March
The biopharma announced full-year 2018 operating results.
Here's Why Renewable Energy Group Lost 17.4% in March
The biodiesel leader reported full-year 2018 operating results.
Here's Why PhaseBio Pharmaceuticals Rose as Much as 32.5% Today
The company made two major announcements in the last 24 hours.